
    
      ECOSPOR is a Phase 2, multicenter, randomized, double blind, placebo controlled clinical
      study with 2 treatment arms (SER-109 or placebo). Patients who have diarrhea and a positive
      C. difficile test result on a stool sample, and who have responded to standard of care
      antibiotic treatment will receive study drug on Day 1.

      Those patients who experience a recurrence of CDI up to 8 weeks after SER 109 or placebo
      treatment will be offered an opportunity to enroll in an open label SER 109 extension study
      (Study SERES 005).
    
  